Near Miss or Standard of Care? <i>DPYD</i> Screening for Cancer Patients Receiving Fluorouracil

Near Miss or Standard of Care? <i>DPYD</i> Screening for Cancer Patients Receiving Fluorouracil

5-fluorouracil (5-FU) and its pro-drug capecitabine are widely used anticancer agents. Most 5-FU catabolism is dependent on dihydropyrimidine dehydrogenase (DPD) encoded by the <i>DPYD</i> gene, and <i>DPYD</i> variants that reduce DPD function increase 5-FU toxicity. Most DP...

Full description

Bibliographic Details
Main Authors: Lauren E. Winquist, Michael Sanatani, Richard B. Kim, Eric Winquist
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Current Oncology
Subjects:
fluoropyrimidines
dihydropyrimidine dehydrogenase
cancer
adverse effects
single nucleotide polymorphisms
drug therapy
Online Access:https://www.mdpi.com/1718-7729/28/1/12

Internet

https://www.mdpi.com/1718-7729/28/1/12

Similar Items